Pfizer and AstraZeneca slide as Moderna's rival COVID-19 vaccine shows strong efficacy

• Strong preliminary data results from Moderna's COVID-19 vaccine has spurred a selloff in rival vaccine developers Pfizer, BioNTech, and AstraZeneca.
• Moderna said on Monday that its COVID-19 vaccine candidate demonstrated an efficacy rate of 94.5% in a trial of more than 30,000 patients.
• Last week, Pfizer and its partner BioNTech said its COVID-19 vaccine candidate demonstrated an efficacy rate of more than 90% in a trial of 44,000 patients.
• AstraZeneca could release interim data on its COVID-19 vaccine as early as December, according to the University of Oxford, who partnered with AstraZeneca to develop a potential vaccine.
• $4.

Another round of strong COVID-19 vaccine data, this time from $4, has put pressure on pharmaceutical companies developing their own vaccine, namely $4, $4, and $4.

On Monday, $4 demonstrated efficacy of 94.5%, putting the company on track to receive emergency use authorization from the FDA by the end of this year.

$4 on Monday following the release of its data.

It may feel like déjà vu for investors, as $4 that its COVID-19 vaccine candidate demonstrated efficacy of more than 90%.

But now, investors may be picking sides in terms of a vaccine developer, as there are marked differences between the two vaccine candidates.

Read more: $4

Besides a higher demonstrated efficacy rate, Moderna's vaccine $4 for up to 30 days, where as Pfizer's vaccine candidate needs to be stored at frigid temperatures of negative-70 degrees Celsius for up to 15 days.

With complex needs required for the storage of Pfizer's COVID-19 vaccine, including freezer farms and dry ice suitcases, it could hinder the swift distribution of the vaccine in a way that wouldn't impact Moderna's vaccine.

Shares of Pfizer slipped as much as 4.4% on Monday, while AstraZeneca lost 1.7% at intraday lows. BioNTech, Pfizer's partner in the development of the COVID-19 vaccine, fell as much as 14%.

AstraZeneca is also in the midst of testing its own COVID-19 vaccine, and according to the University of Oxford, the company could release interim data on its trials by December. Investors sent shares down as much as 2% in pre-market trades on Monday.

Moderna's vaccine news is sending ripple effects through the market on Monday, as different groups of stocks trade $4 and $4 on the prospect that a safe reopening of the economy is within reach.

Read more: $4